09:28 AM EST, 03/07/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday in an investor meeting that early data from the phase 1 trial evaluating the pill version of its experimental obesity drug amycretin showed a weight loss of 13.1% after 12 weeks.

This is higher than the trial results for Wegovy, the company's popular obesity drug, which had shown about 6% weight loss after 12 weeks, according to a Reuters report.

Novo Nordisk ( NVO ) said it expects the phase 1 trial for the injectable version of amycretin to finish in 2025.

Shares of the company were up more than 7% in recent Thursday premarket activity.

Price: 133.68, Change: +8.93, Percent Change: +7.16